SRC and breast cancer: Interestingly, while individual targeting of Src or ERK maintains dormancy in vitro (Barkan et al., 2010), a combinatorial approach using a Src (AZD0530) and the mitogen-activated protein kinase1/2 (MEK1/2) targeting inhibitor (AZD6244) eradicates dormant breast cancer cells both in vitro and in vivo (El Touny et al., 2014).